In October 2006, Teva settled a patent dispute with the Purdue Frederick Company and certain of its affiliates pertaining to Teva's generic version of Purdue's OxyContin tablets.
The settlement provided a full release of Teva and its distributors, purchasers and patients and requires Teva to cease sales of the product upon the occurrence of certain contingencies.
Oxycontin tablets are controlled-release drugs that are prescribed for moderate to severe pain when relief is needed for an extended period of time.